NCT06438055View on ClinicalTrials.gov

Clinical Treatment of Refractory Breast Cancer Based on Organoid Drug Sensitivity Results

NANot yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2026

Conditions
Refractory Breast Cancer
Interventions
OTHER

Chemotherapy and targeted-therapy guided by organoid drug sensitivity test

This study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment. This study aims to evaluate the clinical effectiveness of treatment plans guided by organoid drug sensitivity tests.

All Listed Sponsors
collaborator

Kingbio Medical (Beijing) Co., Ltd.

UNKNOWN

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER

NCT06438055 - Clinical Treatment of Refractory Breast Cancer Based on Organoid Drug Sensitivity Results | Biotech Hunter | Biotech Hunter